These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18666801)

  • 1. Therapeutic use of nicergoline.
    Winblad B; Fioravanti M; Dolezal T; Logina I; Milanov IG; Popescu DC; Solomon A
    Clin Drug Investig; 2008; 28(9):533-52. PubMed ID: 18666801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of nicergoline as an agent for management of cognitive function disorders.
    Saletu B; Garg A; Shoeb A
    Biomed Res Int; 2014; 2014():610103. PubMed ID: 25243157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.
    Fioravanti M; Flicker L
    Cochrane Database Syst Rev; 2001; 2001(4):CD003159. PubMed ID: 11687175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic potential and possibilities of using of sermion (nicergoline) in neurological practice].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):119-22. PubMed ID: 21434467
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 6. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.
    Saletu B; Paulus E; Linzmayer L; Anderer P; Semlitsch HV; Grünberger J; Wicke L; Neuhold A; Podreka I
    Psychopharmacology (Berl); 1995 Feb; 117(4):385-95. PubMed ID: 7604138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study.
    Battaglia A; Bruni G; Ardia A; Sacchetti G
    J Am Geriatr Soc; 1989 Apr; 37(4):295-302. PubMed ID: 2646350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease.
    Zang G; Fang L; Chen L; Wang C
    Mol Med Rep; 2018 May; 17(5):7293-7300. PubMed ID: 29568940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.
    Fioravanti M; Nakashima T; Xu J; Garg A
    BMJ Open; 2014 Jul; 4(7):e005090. PubMed ID: 25079927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ergotamine and nicergoline - facts and myths.
    Zajdel P; Bednarski M; Sapa J; Nowak G
    Pharmacol Rep; 2015 Apr; 67(2):360-3. PubMed ID: 25712664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered neurotransmission and signal transduction: targets for nicergoline treatment.
    Winblad B
    Dement Geriatr Cogn Disord; 1997; 8 Suppl 1():2-5. PubMed ID: 9205832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nicergoline treatment in Parkinson's disease associated with dementia.
    Lee S; Na SH; Chung YA; Jeong H; Song IU
    J Clin Neurosci; 2019 Dec; 70():136-139. PubMed ID: 31431403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
    Takemoto M; Ohta Y; Hishikawa N; Yamashita T; Nomura E; Tsunoda K; Sasaki R; Tadokoro K; Matsumoto N; Omote Y; Abe K
    J Alzheimers Dis; 2020; 76(2):769-772. PubMed ID: 32568205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicergoline in the treatment of dizziness in elderly patients. A review.
    Felisati G; Pignataro O; Di Girolamo A; Bruno E; Alessandrini M; Guidetti G; Monzani D; Beldi AM; Mira E; Benazzo M; Pallestrini E; Caligo G; Casani A; Battaglia A
    Arch Gerontol Geriatr Suppl; 2004; (9):163-70. PubMed ID: 15207410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection and aging of the cholinergic system: a role for the ergoline derivative nicergoline (Sermion).
    Giardino L; Giuliani A; Battaglia A; Carfagna N; Aloe L; Calza' L
    Neuroscience; 2002; 109(3):487-97. PubMed ID: 11823061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias.
    Crook TH
    Dement Geriatr Cogn Disord; 1997; 8 Suppl 1():22-6. PubMed ID: 9205835
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
    Fioravanti M; Yanagi M
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000269. PubMed ID: 15846601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of primary dementia based on modern concepts].
    Nervenarzt; 1995 May; 66(5 Suppl):1-4. PubMed ID: 9131089
    [No Abstract]   [Full Text] [Related]  

  • 19. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia.
    Herrmann WM; Stephan K; Gaede K; Apeceche M
    Dement Geriatr Cogn Disord; 1997; 8(1):9-17. PubMed ID: 8997547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDP-choline: pharmacological and clinical review.
    Secades JJ; Frontera G
    Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.